Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
NPJ Breast Cancer|May 10, 2022
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancerAdrienne G Waks, Neelam V Desai, Tianyu Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I TrialAdrienne G Waks, Elia Segui, Tianyu Li, et al.
Journal of the American College of Surgeons|May 17, 2023
Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical TrialAnna Weiss, Tianyu Li, Neelam V Desai, et al.
JAMA Oncology|April 27, 2023
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and PertuzumabAdrienne G Waks, Esther R Ogayo, Laia Paré, et al.
Biorxiv : the Preprint Server for Biology|December 9, 2024
An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancerKenichi Shimada, Daniel E Michaud, Yvonne Xiaoyong Cui, et al.
JAMA Oncology|June 25, 2026
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe TrialPaolo Tarantino, Tianyu Li, Esther Ritah Ogayo, et al.
Nature Communications|November 28, 2025
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trialAdrienne G Waks, Jingxin Fu, Xiangying Chu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative ChemotherapyAdrienne G Waks, Daniel G Stover, Jennifer L Guerriero, et al.
JAMA Oncology|April 27, 2023
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without PertuzumabCoralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, et al.
The Lancet. Oncology|March 1, 2023
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trialSara M Tolaney, Paolo Tarantino, Noah Graham, et al.
Pageof 5